Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001837416 | SCV002098009 | uncertain significance | Tatton-Brown-Rahman overgrowth syndrome | 2020-06-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001837416 | SCV003261029 | uncertain significance | Tatton-Brown-Rahman overgrowth syndrome | 2023-10-23 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 38 of the DNMT3A protein (p.Arg38His). This variant is present in population databases (rs369618387, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with DNMT3A-related conditions. ClinVar contains an entry for this variant (Variation ID: 1341936). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003416488 | SCV004109515 | uncertain significance | DNMT3A-related disorder | 2024-05-01 | no assertion criteria provided | clinical testing | The DNMT3A c.113G>A variant is predicted to result in the amino acid substitution p.Arg38His. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.017% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |